PBS News Hour second part; How a crumbling antibiotics infrastructure could yield “catastrophe”
Big pharma companies won’t buy antibiotics from small start-up companies because they can’t see how to make them profitable. The small start-ups can’t do it themselves because they can’t sell to hospitals at a high enough price to stay afloat. Without new antibiotic options, we could be facing another COVID-19 scale catastrophe without proper preparation.
